{"id":"NCT02106494","sponsor":"Heron Therapeutics","briefTitle":"A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC","officialTitle":"A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2014-04-08","resultsPosted":"2016-12-28","lastUpdate":"2016-12-28"},"enrollment":942,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chemotherapy-induced Nausea and Vomiting"],"interventions":[{"type":"DRUG","name":"APF530","otherNames":[]},{"type":"DRUG","name":"Ondansetron","otherNames":[]},{"type":"DRUG","name":"Ondansetron placebo","otherNames":[]},{"type":"DRUG","name":"APF530 placebo","otherNames":[]},{"type":"DRUG","name":"Fosaprepitant","otherNames":[]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"APF530 500 mg SC","type":"EXPERIMENTAL"},{"label":"ondansetron 0.15 mg/kg IV","type":"ACTIVE_COMPARATOR"}],"summary":"The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (\\> 24-120 hours) complete response (CR) rate (defined as no emesis and no use of rescue medications) in subjects receiving highly emetogenic chemotherapy (HEC) as defined by the 2011 ASCO CINV guidelines","primaryOutcome":{"measure":"Delayed Phase Complete Response (CR) Rate","timeFrame":"24 - 120 Hours","effectByArm":[{"arm":"APF530 + Fosaprepitant + Dexamethasone","deltaMin":64.7,"sd":null},{"arm":"Ondansetron + Fosaprepitant + Dexamethasone","deltaMin":56.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":18},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":["26997579"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":456},"commonTop":["Injection site bruising","Injection site pain","Fatigue","Injection site erythema","Constipation"]}}